Evidence map›Paper›PMID 32423330›Full record

ReviewJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2020

Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update.

Honglei Ren, Ranran Han, Xuemei Chen, Xi Liu, Jieru Wan, Limin Wang, Xiuli Yang, Jian Wang

Abstract readReview
In one paragraph

Review in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Role of beta-blocker therapy on the sympathetic effects in stroke heart syndrome.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Honglei RenDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ranran HanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Xuemei ChenDepartment of Human Anatomy, Basic Medical College of Zhengzhou University, Zhengzhou, China.
Xi LiuDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jieru WanDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Limin WangDepartment of Neurology, Guangdong Neuroscience Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Xiuli YangDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jian WangDepartment of Human Anatomy, Basic Medical College of Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-2291-640X

Funding

Neuroprotective effect of flavanol (-) epicatechin after intracerebral hemorrhageR01AT007317 · NCCIH · JOHNS HOPKINS UNIVERSITY · PI WANG, JIAN · 2012 to 2016
$2.0M
PGE2 EP1 and EP3 receptors as therapeutic targets in intracerebral hemorrhageR01NS078026 · NINDS · JOHNS HOPKINS UNIVERSITY · PI WANG, JIAN · 2012 to 2016
$1.8M
NCCIH NIH HHS R01 AT007317NINDS NIH HHS R01 NS078026
6 · The paper itself

Abstract

Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality and disability but no specific or effective treatment. In the last two decades, much has been learned about the pathologic mechanisms of ICH. It is now known that after ICH onset, immune and inflammatory responses contribute to blood-brain barrier disruption, edema development, and cell death processes, jointly resulting in secondary brain injury. However, the translation of potential therapies from preclinical to clinical success has been disappointing. With the development of new laboratory technology, recent progress has been made in the understanding of ICH pathomechanisms, and promising therapeutic targets have been identified. This review provides an update of recent progress on ICH and describes the prospects for further preclinical studies in this field. Our goal is to discuss new therapeutic targets and directions for the treatment of ICH and promote the effective transformation from preclinical to clinical trials.

Indexed as

AnimalsBlood-Brain BarrierCerebral HemorrhageClinical Trials as TopicEncephalitisHumansMacrophagesimmune interventionsinflammationIntracerebral hemorrhagemicrogliasecondary injury

Identifiers

PMID32423330
PMCPMC7446569

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.